Cargando…
Incidence of Disease Flare After BNT162b2 Coronavirus Disease 2019 Vaccination in Patients With Rheumatoid Arthritis in Remission
Autores principales: | Bixio, Riccardo, Bertelle, Davide, Masia, Marco, Pistillo, Francesca, Carletto, Antonio, Rossini, Maurizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652957/ https://www.ncbi.nlm.nih.gov/pubmed/34472714 http://dx.doi.org/10.1002/acr2.11336 |
Ejemplares similares
-
Rheumatoid arthritis and myasthenia gravis: a case-based review of the therapeutic options
por: Bixio, Riccardo, et al.
Publicado: (2022) -
Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023) -
Rheumatoid arthritis patients with predominantly tender joints rarely achieve clinical remission despite being in ultrasound remission
por: Hammer, Hilde Berner, et al.
Publicado: (2021) -
The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis
por: Picchianti Diamanti, Andrea, et al.
Publicado: (2023) -
Use of rheumatoid arthritis impact of disease (RAID) in routine care; identification of DAS28 remission and unmet patient-reported outcomes
por: Mistry, Jatin, et al.
Publicado: (2020)